Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Res. 2014 Oct 6;74(23):7014–7023. doi: 10.1158/0008-5472.CAN-14-1220

Figure 6. Anti-NGF attenuates spontaneous and movement-evoked bone cancer pain behaviors.

Figure 6

(A) Time spent in spontaneous nocifensive behavior by anti-NGF-treated mice (closed rectangles) with bone scores of 1-2 (minimal bone destruction, early-stage bone cancer disease), 3-4 (moderate bone destruction), and 5-10 (severe to extreme bone destruction with fracture, late-stage bone cancer disease) was significantly reduced as compared to vehicle-treated mice (open rectangles). (B) Anti-NGF-treated mice (closed circles) spent significantly less time in spontaneous nocifensive behavior than vehicle-treated mice (open circles) at Days 14, 21, and 28 post-cancer cell injection. (C) Weight-bearing ability of tumor-bearing hind limbs of anti-NGF-treated mice (closed circles) was preserved throughout the study, whereas the weight-bearing ability of vehicle-treated mice (open circles) was significantly reduced at Days 21 and 28 post-cancer cell injection. (D) Impaired limb use in anti-NGF-treated mice (closed rectangles) was significantly reduced at Day 28 post-cancer cell injection, as compared to vehicle-treated mice (open rectangles). NCTC 2472 + vehicle, n=36; NCTC 2472 + anti-NGF, n=24. Error bars represent SEM; *p<0.05, one-way ANOVA.